Log in
Enquire now
‌

US Patent 10584174 Anti-Dkk-1-anti-RANKL bispecific antibody compounds

Patent 10584174 was granted and assigned to Eli Lilly and Company on March, 2020 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Patent abstractTimelineTable: Further ResourcesReferences
Is a
Patent
Patent

Patent attributes

Patent Applicant
Eli Lilly
Eli Lilly
Current Assignee
Eli Lilly
Eli Lilly
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10584174
Date of Patent
March 10, 2020
Patent Application Number
15570756
Date Filed
May 12, 2016
Patent Citations
‌
US Patent 10150800 EGFR-binding modular recognition domains
Patent Primary Examiner
‌
Claire Kaufman
Patent abstract

Bispecific antibody compounds, and methods of using same, are provided which bind and neutralize Dkk-1 and RANKL and which are useful as adjuncts to spinal fusion surgery or as agents for bone healing or treating conditions associated with bone loss or degeneration.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10584174 Anti-Dkk-1-anti-RANKL bispecific antibody compounds

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.